We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
Ephrin receptor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='3fxx' size=' | + | <StructureSection load='3fxx' size='350' side='right' scene='45/450911/Cv/1' caption='Human ephrin A3 receptor (magenta) complex with peptide substrate (green), nucleotide derivative and Mg+2 ion [[3fxx]]'> |
== Function == | == Function == | ||
| Line 27: | Line 27: | ||
**[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | **[[3kka]] - hEPHR A1 SAM+ hEPH A2 SAM – human<BR /> | ||
**[[3hil]] - hEPHR A1 SAM<br /> | **[[3hil]] - hEPHR A1 SAM<br /> | ||
| - | **[[ | + | **[[2k1k]] - hEPHR A1 transmembrane domain – NMR<BR /> |
**[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR /> | **[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR /> | ||
*Ephrin A2 receptor | *Ephrin A2 receptor | ||
| Line 33: | Line 33: | ||
**[[2x10]], [[3fl7]] - hEPHR A2 ectodomain<BR /> | **[[2x10]], [[3fl7]] - hEPHR A2 ectodomain<BR /> | ||
**[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | **[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | ||
| - | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]] - hEPHR A2 kinase domain<BR /> | + | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain<BR /> |
*''Ephrin A2 receptor binary complex''<br /> | *''Ephrin A2 receptor binary complex''<br /> | ||
| Line 41: | Line 41: | ||
**[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | **[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | ||
**[[2kso]] - hEPHR A2 SAM + SHIP2<br /> | **[[2kso]] - hEPHR A2 SAM + SHIP2<br /> | ||
| + | **[[5i9v]], [[5i9w]] - hEPHR A2 kinase domain + inhibitor<br /> | ||
| + | **[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | ||
| + | |||
*Ephrin A3 receptor | *Ephrin A3 receptor | ||
| + | |||
**[[2qo2]], [[2qob]], [[2gsf]] - hEPHR A3 kinase domain<BR /> | **[[2qo2]], [[2qob]], [[2gsf]] - hEPHR A3 kinase domain<BR /> | ||
**[[2qok]], [[2qol]], [[2qon]], [[2qoo]], [[2qod]], [[2qof]], [[2qoi]] - hEPHR A3 kinase domain (mutant) <BR /> | **[[2qok]], [[2qol]], [[2qon]], [[2qoo]], [[2qod]], [[2qof]], [[2qoi]] - hEPHR A3 kinase domain (mutant) <BR /> | ||
**[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | **[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | ||
**[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | **[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | ||
| - | **[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]] - hEPHR A3 kinase domain + inhibitor<br /> | + | **[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]], [[4p4c]], [[4twn]], [[4two]] - hEPHR A3 kinase domain + inhibitor<br /> |
**[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | **[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | ||
| + | **[[4l0p]] - hEPHR A3 LBD + Ephrin-A5<br /> | ||
| + | |||
*Ephrin A4 receptor | *Ephrin A4 receptor | ||
| + | |||
**[[2wo1]], [[3ckh]] - hEPHR A4 LBD<BR /> | **[[2wo1]], [[3ckh]] - hEPHR A4 LBD<BR /> | ||
**[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | **[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | ||
| Line 58: | Line 65: | ||
**[[2wo3]] - hEPHR A4 LBD + ephrin A2 receptor-binding domain<BR /> | **[[2wo3]] - hEPHR A4 LBD + ephrin A2 receptor-binding domain<BR /> | ||
| - | **[[4w4z]], [[4w50]] - hEPHR A4 LBD (mutant) + peptide<br /> | + | **[[4w4z]], [[4w50]], [[5jr2]] - hEPHR A4 LBD (mutant) + peptide<br /> |
**[[2wo2]], [[3gxu]] - hEPHR A4 LBD + ephrin B2 receptor-binding domain<br /> | **[[2wo2]], [[3gxu]] - hEPHR A4 LBD + ephrin B2 receptor-binding domain<br /> | ||
**[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | **[[4bk5]], [[4bka]], [[4m4r]] - hEPHR A4 ectodomain + ephrin A5 LBD<br /> | ||
| Line 64: | Line 71: | ||
**[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | **[[2xyu]] – mEPHR A4 kinase domain + inhibitor<br /> | ||
**[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | **[[2y6o]] – mEPHR A4 kinase domain + cancer drug<br /> | ||
| + | |||
*Ephrin A5 receptor | *Ephrin A5 receptor | ||
| + | |||
**[[2r2p]] - hEPHR A5 kinase domain<BR /> | **[[2r2p]] - hEPHR A5 kinase domain<BR /> | ||
**[[1shx]] - mEPHR A5 <br /> | **[[1shx]] - mEPHR A5 <br /> | ||
| Line 73: | Line 82: | ||
**[[2rei]] - hEPHR A7 kinase domain<BR /> | **[[2rei]] - hEPHR A7 kinase domain<BR /> | ||
**[[3dko]] – hEPHR A7 kinase domain + inhibitor | **[[3dko]] – hEPHR A7 kinase domain + inhibitor | ||
| + | |||
*Ephrin A8 receptor | *Ephrin A8 receptor | ||
| + | |||
**[[3kul]] - hEPHR A8 kinase domain<BR /> | **[[3kul]] - hEPHR A8 kinase domain<BR /> | ||
**[[1x5l]] – hEPHR A8 fn3 domain – NMR<BR /> | **[[1x5l]] – hEPHR A8 fn3 domain – NMR<BR /> | ||
**[[1ucv]] - hEPHR A8 SAM – NMR<BR /> | **[[1ucv]] - hEPHR A8 SAM – NMR<BR /> | ||
| + | |||
*Ephrin B1 receptor | *Ephrin B1 receptor | ||
| + | |||
**[[2eao]] – hEPHR B1 SAM – NMR<BR /> | **[[2eao]] – hEPHR B1 SAM – NMR<BR /> | ||
**[[2djs]] - hEPHR B1 fn3 domain – NMR<BR /> | **[[2djs]] - hEPHR B1 fn3 domain – NMR<BR /> | ||
**[[3zfx]] - hEPHR B1 kinase domain<br /> | **[[3zfx]] - hEPHR B1 kinase domain<br /> | ||
| + | |||
*Ephrin B2 receptor | *Ephrin B2 receptor | ||
| + | |||
**[[3etp]] – hEPHR B2<BR /> | **[[3etp]] – hEPHR B2<BR /> | ||
**[[1b4f]] - hEPHR B2 SAM<br /> | **[[1b4f]] - hEPHR B2 SAM<br /> | ||
| Line 87: | Line 102: | ||
**[[1iko]] - mEPHR B2 ectodomain<br /> | **[[1iko]] - mEPHR B2 ectodomain<br /> | ||
**[[2i85]] - hEPHR B2 ectodomain<br /> | **[[2i85]] - hEPHR B2 ectodomain<br /> | ||
| + | **[[3zfm]] - hEPHR B2 kinase domain<br /> | ||
**[[1sgg]] - mEPHR B2 SAM – chicken - NMR<BR /> | **[[1sgg]] - mEPHR B2 SAM – chicken - NMR<BR /> | ||
| Line 98: | Line 114: | ||
*Ephrin B3 receptor | *Ephrin B3 receptor | ||
| + | |||
**[[3p1i]] – hEPHR B3 LBD<BR /> | **[[3p1i]] – hEPHR B3 LBD<BR /> | ||
**[[3zfy]] - hEPHR B3 kinase domain<br /> | **[[3zfy]] - hEPHR B3 kinase domain<br /> | ||
| + | **[[5l6o]], [[5l6p]] - hEPHR B3 kinase domain (mutant) + inhibitor<br /> | ||
| + | |||
*Ephrin B4 receptor | *Ephrin B4 receptor | ||
| + | |||
**[[2qkq]] – hEPHR B4 SAM<BR /> | **[[2qkq]] – hEPHR B4 SAM<BR /> | ||
**[[2e7h]] – hEPHR B4 fn3 domain - NMR<BR /> | **[[2e7h]] – hEPHR B4 fn3 domain - NMR<BR /> | ||
Revision as of 09:44, 1 May 2017
| |||||||||||
3D Structures of ephrin receptors
Updated on 01-May-2017
References
- ↑ Pitulescu ME, Adams RH. Eph/ephrin molecules--a hub for signaling and endocytosis. Genes Dev. 2010 Nov 15;24(22):2480-92. doi: 10.1101/gad.1973910. PMID:21078817 doi:http://dx.doi.org/10.1101/gad.1973910
- ↑ Genander M, Frisen J. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol. 2010 Oct;22(5):611-6. doi: 10.1016/j.ceb.2010.08.005. PMID:20810264 doi:http://dx.doi.org/10.1016/j.ceb.2010.08.005
- ↑ Davis TL, Walker JR, Allali-Hassani A, Parker SA, Turk BE, Dhe-Paganon S. Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 2009 Aug;276(16):4395-404. PMID:19678838 doi:http://dx.doi.org/10.1111/j.1742-4658.2009.07147.x
